BSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper. Multiple Myeloma (MM) is a clonal bone marrow disorder of plasma cells, typically preceded by precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and Smouldering Myeloma (SMM). SMM represents a significant plasma cell clone, with 10% to 59% of plasma cells present in the bone marrow, yet without causing any organ or tissue impairment.
Historical data show that the risk of SMM progressing to MM or related disorders is 10% per year for the first five years post-diagnosis, decreasing to 3% for the next five years, and further to 1% over the following decade. This paper aims to provide evidence-based recommendations for assessing and managing patients with SMM, recognising the need for timely intervention based on individual risk factors. The guidelines detail risk stratification, diagnostic criteria, and management strategies that will empower healthcare professionals to optimise patient outcomes and enhance the quality of life for individuals living with Smouldering Myeloma.
Discover evidence-based recommendations, including clear patient support, tailored vaccination strategies, and more.
Use Cases
Type
Source
Content Collection
You might also like
IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Step into the forefront of myeloma treatment with this latest publication from the International Myeloma Working Group immunotherapy committee.
IMWG GuidelineNICE guidelines on Spinal metastases and metastatic spinal cord compression [NG234]
This NICE guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC).
NICE GuidelineIMWG recommendations on the management of multiple myeloma-related renal impairment
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
IMWG GuidelineIMWG consensus guidelines and recommendations for infection prevention in myeloma
Infection poses a significant risk to patients with multiple myeloma, contributing to high rates of morbidity and mortality. This consensus statement from the International Myeloma Society outlines essential guidelines for infection prevention
IMWG GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
IMWG recommendations for the treatment of multiple myeloma-related bone disease
This guideline, authored by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the current evidence and offers management recommendations for myeloma-related bone disease.
IMWG GuidelineScottish referral guidelines for suspected cancer
The Scottish Referral Guidelines for Suspected Cancer were created to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist.
Other GuidelineNICE guideline on Acute kidney injury: prevention, detection and management [NG148]
This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
NICE GuidelineIMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
IMWG GuidelineMY-RADS guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Other Guideline
